The CFO of one of the largest US financial institutions identified over $80 million in annual pharmacy benefit expenditures on over 1 million prescriptions, but lacked any mechanism to validate individual claims and ensure
accuracy of program expenses.

TRUVERIS reviewed the client's PBM contract, analyzed 100% of the individual claims through its proprietary technology, and provided a validated summary within 24 hours

That summary identified initial savings of over $7M dollars stemming from duplicate claims, overcharges, failure to provide lower cost alternatives, and inactive drug codes. With TRUVERIS, the client successfully negotiated a beneficial flat rate with the PBM, capping annual cost increases at an advantageous rate.